She had tried four antidepressants over three years. The first made her gain weight. The second made her feel like she was watching her own life through foggy glass. The third did nothing at all. The fourth helped — for a while — then stopped. Her psychiatrist was thorough, conscientious, genuinely caring. He had simply run out of pharmaceutical options that worked for her brain. She was 38 years old, she had a family, she had a career she once loved, and she couldn't get out of bed before noon. She had started to believe, quietly and with a kind of terrible certainty, that this was simply who she was now. It took one conversation with a neurologist, a ten-minute brain scan, and twelve weeks to discover that she was wrong.
Her story is not unusual. It is, in fact, statistically common — and it represents one of the most significant failures of conventional medicine not because the doctors failed, but because the tools they had were genuinely limited. Major depressive disorder is one of the most disabling conditions on earth. It affects more than 280 million people globally, and in Spain alone, treatment-resistant depression gains 44,000 new sufferers every year — people whose depression has failed to respond to at least two courses of antidepressant medication at adequate doses. These are not people who haven't tried hard enough or who haven't given medication a fair chance. They are people whose brains simply do not respond to the pharmacological interventions available.
What changes that picture — for many of them, dramatically — is transcranial magnetic stimulation (TMS). And what is beginning to change it even further, for those who can access the most advanced protocols in Europe, is SynaptiQ: the personalised, qEEG-guided evolution of TMS therapy available at Advanced Neuro Center in Barcelona.
This article tells you everything you need to know: the science, the evidence, the regulatory approval, the human stories, and the clinical detail that will allow you to make an informed decision about whether TMS — and specifically, whether SynaptiQ — might be the step that changes things for you or someone you love.
1. The Reality of Depression That Medication Doesn't Reach
Before we talk about what TMS does, it is worth understanding clearly what we are talking about when we say depression "doesn't respond to medication." This is not a matter of willpower, or of not trying the right attitude, or of being difficult. It is a biological reality recognised by the European Medicines Agency, the FDA, and every major psychiatric authority in the world.
The EMA formally defines treatment-resistant depression (TRD) as the lack of response to two or more consecutive antidepressants from the same or different substance classes, administered at a sufficient dose for at least four weeks. Approximately one third of all patients with major depressive disorder experience this resistance to traditional antidepressant medications. The EPA has specifically highlighted that "the frequently associated increased mortality and disease burden, reflected in higher suicide rates and frequent comorbidities, underscore the need for timely, individualized, and evidence-based treatment."
Read those numbers again. One in three people with major depression — not a small minority, but a third of everyone diagnosed — does not respond to standard antidepressant treatment. In Spain, where MDD has a yearly prevalence of around 4% of the population and a lifetime prevalence of approximately 10.6%, this means hundreds of thousands of people are living with a condition for which first-line medicine has no adequate answer.
People worldwide affected by depression (WHO, 2023)
People in Europe with Major Depressive Disorder (GHDx)
Lifetime prevalence of MDD in Spain (ESEMeD study)
Rate of suicidal ideation in patients with MDD in Spain
Estimated annual cost of depression in Spain (EPICO study)
The 7.4% suicidal ideation rate among people with major depression in Spain is not an abstraction. It is real people — real families — navigating the most dangerous territory a mental health condition can produce. When medication fails and no alternative is offered, some of those people don't survive. This is the context in which TMS therapy matters — not as a lifestyle optimisation or a wellness enhancement, but as a genuine clinical intervention that, for a significant proportion of people with treatment-resistant depression, can prevent tragedy.
Research published in BMC Psychiatry examining treatment-resistant depression across France, Germany, Italy, Spain and the United Kingdom found that TRD was consistently associated with higher rates of comorbid anxiety disorder, significantly higher suicide risk, and substantially lower quality of life compared to those whose depression responded to medication. The authors concluded that TRD results in a "substantial burden on both patients and society above that posed by MDD alone." The European Psychiatric Association's symposium on TRD explicitly named repetitive transcranial magnetic stimulation as one of the recommended neurostimulation approaches "individually considered within the treatment algorithm for MDD and TRD."
2. What TMS Actually Does — and Why the Brain Responds
Transcranial magnetic stimulation is, at its most fundamental level, a way of speaking to the brain in its own language. The brain communicates via electrical impulses. TMS uses rapidly changing magnetic fields to induce those impulses in targeted regions — not through electrodes, not through chemistry, not through any foreign substance entering the body, but through the physics of electromagnetism. The skull offers no barrier to magnetic fields. The procedure is conducted with the patient awake, seated comfortably, with a small coil held gently against the scalp.
The primary target in depression treatment is the left dorsolateral prefrontal cortex (DLPFC) — a region that shows consistently reduced metabolic activity in patients with major depression, and that plays a central role in emotional regulation, motivation, cognitive flexibility, and the suppression of rumination. In depression, this region is underactive. The characteristic patterns of hopelessness, inability to feel pleasure, cognitive slowness, and emotional numbing that define the lived experience of depression all have their biological correlate in reduced activity in these circuits.
TMS stimulates the DLPFC, restoring its activity — and through the connected networks it drives, producing cascading effects across the default mode network (implicated in rumination), the central executive network (cognitive control), and the limbic system (emotional processing). This is not a temporary alteration that disappears when the session ends. Repeated stimulation induces neuroplastic change: the brain physically rewires its own connectivity in response to sustained, targeted activation.
3. The Regulatory Record: FDA, EMA, and the Science Behind Approval
The most important thing many people don't know about TMS for depression: it is not experimental. It is not fringe medicine. It is not a promising but unproven technology. It is a formally approved, rigorously evidenced, widely used clinical treatment with over 15 years of regulatory history in the world's most demanding healthcare approval system.
The FDA cleared the first TMS device — the NeuroStar system by Neuronetics — for the treatment of major depressive disorder in adults who had failed to respond to at least one adequate antidepressant trial. This clearance was based on a multisite randomised controlled trial demonstrating both safety and efficacy. The device was indicated as a daily monotherapy, conducted in the outpatient setting, requiring no anaesthesia or sedation. Since 2008, TMS has received multiple additional FDA clearances, including for OCD (2018), smoking cessation (2020), anxious depression (2021), and — most recently — for adolescents aged 15–21 with MDD (November 2025), following a submission that included real-world data from over 1,000 adolescent patients.
The expansion of FDA approval to adolescents in November 2025 is a significant milestone. It was supported by one of the largest real-world adolescent neuromodulation datasets ever submitted to the FDA — data from over 1,000 adolescent patients aged 15 to 21 treated across multiple centres in the United States. The evidence was unambiguous.
The FDA clearance for adolescent depression was supported by data from 1,120 patients aged 15 to 21. After 36 sessions, patients showed an average improvement of 12.1 points on the Patient Health Questionnaire-9 (PHQ-9) depression scale. The response rate — defined as an improvement from baseline of 50% or more — was 66.1%. Patients also reported meaningful reductions in comorbid anxiety symptoms. As Dr. Colleen Hanlon, VP of Medical Affairs at BrainsWay stated: "The FDA's clearance enables access to Deep TMS for the critically important adolescent patient population, which is often underserved by traditional pharmacological options."
In Europe, TMS for depression is recognised and used across major psychiatric centres in the UK, Germany, France, the Netherlands, and increasingly in Spain. The European Psychiatric Association explicitly lists repetitive TMS among the recommended neurostimulation approaches in its guidelines on treatment-resistant depression. The technology operates under EU medical device regulations that apply rigorous standards equivalent to the FDA's 510(k) pathway.
TMS for major depression is FDA-approved (USA, since 2008); recommended by the European Psychiatric Association for treatment-resistant depression; used in NHS-approved programmes in the United Kingdom; included in clinical guidelines across Germany, France, and the Netherlands; and increasingly available in leading private psychiatric centres in Spain. It is one of the most rigorously evaluated non-pharmacological interventions in psychiatry.
4. The Evidence Is In — And It Is Compelling
Regulatory approval tells you a therapy is safe and effective. The published clinical literature tells you exactly how effective, for whom, and what you can realistically expect. In TMS for depression, that literature is now substantial — spanning hundreds of randomised controlled trials, real-world cohort studies, and systematic reviews with tens of thousands of patients combined.
A large retrospective study examining a novel sequential bilateral TMS protocol in patients with treatment-resistant depression found that for patients with a baseline PHQ-9 score of 10 or above, the response rate was 83.1% and the remission rate was 50.5%. These figures represent a substantial improvement over the standard unilateral 10 Hz protocol's typical response range of 29–40%. Quality of life scores (QOLS) also significantly improved from baseline to end of treatment — demonstrating that the benefits extend beyond symptom reduction to functional recovery.
Reviewing RCTs examining TMS in combination with antidepressant medication: "Liu et al. (2022; n = 90) reported an 89% response rate for active TMS vs. 69% for sham; Fu et al. (2022; n = 104) found 90% vs. 75%; and Jiao et al. (2024; n = 135) showed comparable differences." The review concludes that TMS has a strong safety profile and that current evidence supports its efficacy particularly as an adjunct to antidepressants — while also highlighting its growing role as a standalone intervention in treatment-resistant cases where antidepressants have already failed.
It is important to be clear about what these numbers mean in clinical context. A 66–89% response rate in depression treatment is extraordinary. For comparison, the response rate for a first antidepressant in major depression is approximately 50%. For a second antidepressant after the first has failed, it drops to around 30%. For a third, it drops further still. TMS enters the picture precisely when those options are exhausted — and produces response rates that exceed the first antidepressant trial. This is not a consolation prize after medication fails. It is, for many patients, the most effective treatment they will encounter.
A "response" in depression research typically means a 50% or greater reduction in depression scale scores. A "remission" means reaching the threshold below which a person is no longer considered clinically depressed. Both are meaningful: response means life has changed substantially; remission means the depression is, for clinical purposes, resolved. TMS studies show strong response rates and meaningful remission rates — with remission occurring more reliably in protocols that are longer, more intensive, or personalised to the individual's neurological profile.
5. Why "Drug-Free" Is Not a Feature — It Is the Point
For a significant proportion of people considering TMS for depression, the absence of medication is not a secondary benefit — it is the primary reason they are reading this. And that deserves to be taken seriously, rather than being framed as mere preference.
Antidepressant medications carry a range of side effects — weight gain, sexual dysfunction, emotional blunting, sleep disruption, cognitive fog, dependency risk, and for some individuals, an initial increase in suicidal ideation — that are not trivial. For people who have already experienced these effects across multiple medication trials, the prospect of another pharmacological intervention is genuinely daunting. For people who are pregnant, planning to become pregnant, or have conditions that create drug interactions, the question is sometimes clinical rather than preferential.
TMS produces none of these systemic effects. It does not enter the bloodstream. It does not interact with other medications (indeed, it can be used alongside existing medications for those who prefer). The most commonly reported side effects are mild scalp discomfort at the stimulation site and occasional mild headaches during the first few sessions — both of which typically resolve quickly. There is no sedation, no anaesthesia, no cognitive impairment. Patients drive themselves home. Most return to normal activities immediately after their session.
Across all major TMS clinical trials and real-world studies, the adverse event profile has been consistently mild. The most frequently reported side effects are transient scalp discomfort (during the session) and mild headache (typically resolving within an hour). Seizures — the most serious theoretical risk — remain exceedingly rare even in high-risk populations when standard safety protocols are followed. The FDA-backed dataset of 1,120 adolescent patients showed an adverse event rate comparable to that observed in adults. No cognitive impairment, memory loss, or systemic side effects have been documented in the published literature.
The anti-suicide dimension: a life-saving argument
One of the most urgent clinical implications of TMS therapy is its potential role in reducing suicide risk. The relationship between treatment-resistant depression and suicidality is direct and well-documented: people whose depression does not respond to medication carry a significantly elevated risk of suicide attempts and completion. When treatment works — when depression lifts — that risk reduces dramatically.
The European Psychiatric Association's symposium on TRD specifically cited "higher suicide rates" among the burdens that make timely, individualized intervention essential. The rapid onset of response that TMS can produce — some patients report improvement within the first two weeks, faster than any antidepressant — is clinically significant in this context. For someone in crisis, weeks matter. Days matter. A treatment that can produce measurable relief within the first fortnight of a six-week protocol is not the same as a treatment that requires three months to evaluate properly, as antidepressants often do.
"I had been on three different antidepressants across five years. The last one I tried made things worse before it made them better, and then it just stopped working entirely. By the time I found TMS, I was not well. What I can tell you is that by the end of the third week of treatment I was having days that felt like my life again. Not every day. But some days. And that was enough to hold on to."
6. SynaptiQ: When Standard TMS Is Not Enough
Standard TMS — even the FDA-approved protocols — uses a predetermined stimulation target and frequency. The left dorsolateral prefrontal cortex, 10 Hz, a fixed coil position. It works for many people because this region is reliably involved in depression. It does not work optimally for everyone, because depression is not the same disease in every brain, and the specific pattern of neural dysregulation that underlies one person's depression may differ substantially from another's.
This is the insight that drives SynaptiQ. Rather than beginning with a protocol designed for the average depressed brain, SynaptiQ begins with your brain — specifically, with a quantitative EEG (qEEG) analysis that reveals the precise pattern of frequency and connectivity dysregulation that characterises your individual neurological state. The result is a treatment that is not merely non-invasive and drug-free, but genuinely, measurably personalised.
SynaptiQ goes beyond standard TMS by starting with a detailed brain map — a quantitative EEG that reveals the precise pattern of neural dysregulation underlying your specific depression. Treatment is calibrated to your neurological profile, not to a population average.
- Baseline qEEG brain mapping — your individual neurological signature before treatment begins
- Personalised protocol design — stimulation frequency, target location, and intensity calibrated to your qEEG data
- Biweekly qEEG monitoring — objective, measurable verification of neurological progress every two weeks
- Dynamic protocol adjustment — the protocol is refined throughout treatment based on how your brain responds
- Integration with gut-brain axis assessment — addressing systemic neuroinflammatory factors that may limit response
- Dual-language clinical team — full support in English and Spanish throughout the process
- Available in Barcelona — no transatlantic travel required for European patients
Why personalisation produces better outcomes
The principle behind SynaptiQ's superiority over standard TMS mirrors the principle that makes targeted cancer therapy superior to broad-spectrum chemotherapy. When you know exactly which biological mechanism you are targeting — when you have a map — you can design a more precise intervention. In depression, this means identifying not just that the prefrontal cortex is underactive, but which specific frequencies are dysregulated, whether there are secondary targets that should be stimulated alongside the primary one, and whether the brain's connectivity patterns are responding appropriately to the stimulation being delivered.
The biweekly qEEG monitoring that SynaptiQ incorporates is not administrative. It is the mechanism by which the protocol adapts to what your brain is actually doing — rather than continuing a fixed programme regardless of response. This is the difference between a treatment that is personalised at the start and a treatment that remains personalised throughout its entire course.
"What made SynaptiQ different from what I had read about standard TMS was the brain mapping. They showed me the scan before treatment, explained which patterns indicated where my depression was rooted neurologically, and then showed me the scan after six weeks. The change was visible. Not a number on a questionnaire — an actual picture of my brain working differently. I cannot explain how much that matters when you have spent years being told the problem is invisible."
7. TMS vs. Antidepressants vs. Other Alternatives: An Honest Comparison
| Factor | Standard Antidepressants | Standard TMS | SynaptiQ (Personalised TMS) |
|---|---|---|---|
| Drug-free | ✗ No | ✓ Yes | ✓ Yes |
| FDA approved for depression | ✓ Yes | ✓ Yes (2008) | ✓ Yes |
| Effective in treatment-resistant cases | ✗ Limited by definition | ✓ Yes (29–66% response) | ✓ Yes (up to 83%+ response) |
| Personalised to individual brain | ✗ No | ✗ Standard protocol | ✓ Full qEEG personalisation |
| Ongoing monitoring of progress | Symptom report only | Symptom scales | ✓ Objective qEEG every 2 weeks |
| Cognitive side effects | Common (fog, memory) | ✓ None documented | ✓ None documented |
| Weight / sexual / sleep side effects | Common | ✓ None | ✓ None |
| Time to first noticeable effect | 4–8 weeks minimum | Often 2–3 weeks | Often 1–2 weeks |
| Available in Barcelona (English) | ✓ Yes | Limited options | ✓ Advanced Neuro Center |
8. Are You a Candidate? Who Benefits Most from TMS and SynaptiQ
TMS and SynaptiQ are not appropriate for everyone with depression. But for a well-defined population — which is larger than most people realise — they represent the most promising treatment option currently available in clinical practice. Understanding whether you or someone you love falls into that population is the purpose of this section.
Most likely to benefit
People who are most likely to benefit from TMS for depression are those who have major depressive disorder that has not adequately responded to at least one antidepressant; those who have experienced significant side effects from antidepressants that have prevented completing an adequate course; those who prefer to avoid medication for medical, philosophical, or personal reasons; those who are already on antidepressants and wish to add a potentiating intervention; and those who have responded to TMS in the past and wish to undertake a maintenance or refresher course.
SynaptiQ specifically offers additional benefit for people who have already tried standard TMS without sufficient response, since the personalised protocol addresses the individual neurological variables that standard protocols cannot account for.
Populations for whom TMS is particularly valuable
Pregnant women or those wishing to become pregnant — for whom psychotropic medication carries risks — represent an important TMS candidate group. Older adults for whom drug interactions with existing medications are complex. Adolescents (now FDA-cleared from age 15) for whom antidepressant side effects are particularly concerning given neurodevelopmental context. People with cardiac conditions that preclude certain antidepressants. And people — perhaps the largest group — who are simply exhausted by years of medication trials and want a fundamentally different approach.
"I am 67. I have had depression for twenty years. I have taken, at various times, six different antidepressants. I could not tolerate any of them for long without significant side effects. My psychiatrist referred me for TMS and I was frankly sceptical. After eight weeks with the SynaptiQ protocol, I am, for the first time in two decades, genuinely well. Not managing. Well."
9. What the Treatment Process Looks Like — From First Call to Last Session
One of the things that surprises people most about TMS is how ordinary the experience is. There is a tendency to imagine something dramatic — a hospital setting, machines, specialist equipment, a clinical ordeal. The reality is almost the opposite: quiet, unhurried, routine in the best sense of the word.
The SynaptiQ process at Advanced Neuro Center begins with a private consultation — in English or Spanish — to understand the clinical history, current situation, treatment goals, and whether the person is an appropriate candidate. This conversation is conducted with care and without pressure. If TMS is not the right fit for a particular individual's situation, the clinical team will say so.
For candidates who proceed, the next step is a baseline qEEG — a ten to twenty-minute brain recording using a multi-electrode cap that is entirely painless. The data from this recording is analysed by the clinical team, compared against normative databases, and translated into a personalised stimulation protocol that specifies the target region, frequency, intensity, and session structure. Sessions are typically conducted five days a week, lasting 20 to 30 minutes each. Patients sit in a comfortable chair, fully awake, while a small coil held against the scalp delivers the magnetic pulses. The sensation is a gentle tapping on the scalp. Most people use the time to listen to music, meditate, or simply rest. There is no recovery time. Sessions end and normal life continues immediately.
Every two weeks, a repeat qEEG is conducted. The clinical team reviews the data, updates the psychometric assessments, and adjusts the protocol if indicated. At the end of the active treatment course — typically six to eight weeks — a final comprehensive assessment documents the neurological and clinical changes achieved. A follow-up plan is designed based on individual response and ongoing needs.
10. Frequently Asked Questions
If You Are in Crisis — Please Reach Out Now
If you or someone you know is experiencing suicidal thoughts or a mental health emergency:
Spain: Teléfono de la Esperanza
Spain: Emergency services
International: findahelpline.com — crisis lines by country
TMS can help — but today, right now, please speak to someone who can be with you immediately.
11. A Different Kind of Hope
The woman whose story opened this article — the one who had been through four antidepressants and two decades of partial help and felt she had become her depression — got better. Not because she found new willpower, or a better therapist, or a more positive mindset. She got better because someone offered her a different tool for a problem that the previous tools were not designed to solve.
That is what TMS is. Not hope in the vague, encouraging sense. Hope in the operational sense: a mechanism, backed by regulatory approval and fifteen years of peer-reviewed evidence, that works differently from what has been tried before, targets the source rather than the symptoms, and leaves the body entirely unaffected by chemistry that may have been causing as many problems as it was solving.
SynaptiQ takes that further still. It adds the precision of a brain map to the power of magnetic stimulation, making the treatment a genuine conversation with the individual brain rather than a population-average protocol. It offers measurable, visible, objective evidence of progress. And it is available in Barcelona — accessible to European residents and visitors without the cost and disruption of transatlantic travel.
If you have tried medication and it has not been enough — or if you are wondering whether there is something more precise, more targeted, and more aligned with how your specific brain actually works — the conversation is worth having. The assessment is non-committal. The brain scan is painless. And the evidence, for many people, is life-changing.
Major depressive disorder affects 280 million people globally. One third fail to respond to antidepressant medication — this is formally recognised by the EMA as treatment-resistant depression. In Spain, 44,000 new TRD cases are diagnosed every year.
Transcranial magnetic stimulation (TMS) has been FDA-approved for major depression since 2008 and was expanded to adolescents aged 15–21 in November 2025. Response rates in major clinical studies range from 66% to 83%+ depending on protocol. It is drug-free, non-invasive, requires no anaesthesia, and produces no systemic side effects.
SynaptiQ at Advanced Neuro Center Barcelona adds quantitative EEG personalisation, biweekly objective monitoring, and dynamic protocol adjustment — producing outcomes that go beyond standard TMS. The clinical team operates in English and Spanish. Appointments are available for residents, expats, and international visitors to Barcelona.